Skip to Content

Teleflex Inc TFX

Morningstar Rating
$206.35 −0.19 (0.09%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Teleflex Earnings: Better Than Expectations; Guidance Reiterated and Valuation Unchanged

Teleflex reported first-quarter earnings that were stronger than our expectations, with solid performances in its interventional and OEM product lines. Management reiterated its previous 2024 guidance for key metrics, and we think the first quarter is solid progress toward these full-year figures. We maintain our fair value estimate of $225 per share and view the stock as fairly valued.

Price vs Fair Value

TFX is trading at a 576% premium.
Price
$206.35
Fair Value
$878.00
Uncertainty
Medium
1-Star Price
$348.76
5-Star Price
$672.70
Economic Moat
Vrfh
Capital Allocation
Rwf

Bulls Say, Bears Say

Bulls

UroLift provides a meaningful clinical benefit in an area of unmet needs. Together with Barrigel, Telelfex has a decent chance of building a strong business in interventional urology.

Bears

Historical acquisitions have not materially improved the company's return on capital, and the pricing and performance of future acquisitions should be carefully monitored.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TFX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$206.54
Day Range
$204.63208.13
52-Week Range
$177.63262.97
Bid/Ask
$178.33 / $229.00
Market Cap
$9.72 Bil
Volume/Avg
476,857 / 373,781

Key Statistics

Price/Earnings (Normalized)
15.11
Price/Sales
3.25
Dividend Yield (Trailing)
0.64%
Dividend Yield (Forward)
0.64%
Total Yield
0.66%

Company Profile

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Core
Total Number of Employees
14,500

Competitors

Valuation

Metric
TFX
BSX
MDT
Price/Earnings (Normalized)
15.1134.7615.21
Price/Book Value
2.165.492.15
Price/Sales
3.257.453.38
Price/Cash Flow
15.0331.6015.05
Price/Earnings
TFX
BSX
MDT

Financial Strength

Metric
TFX
BSX
MDT
Quick Ratio
1.200.941.46
Current Ratio
2.511.662.30
Interest Coverage
4.328.888.86
Quick Ratio
TFX
BSX
MDT

Profitability

Metric
TFX
BSX
MDT
Return on Assets (Normalized)
5.24%9.16%7.75%
Return on Equity (Normalized)
8.81%16.77%13.75%
Return on Invested Capital (Normalized)
7.31%11.67%9.87%
Return on Assets
TFX
BSX
MDT
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncJxcqxfgnhDlbb$142.2 Bil
BDX
Becton Dickinson & CoGvqdcmbzXldxsj$67.8 Bil
ALC
Alcon IncHkqxfgncGrfdyg$44.6 Bil
RMD
ResMed IncPrrssfsdjjXcmkvhl$31.3 Bil
CLPBY
Coloplast A/S ADRVbppqgfzzWmcv$28.0 Bil
WST
West Pharmaceutical Services IncZfxpjhdhpvKypb$24.5 Bil
COO
The Cooper Companies IncDzghnszybXpsjblb$18.8 Bil
BAX
Baxter International IncDngjrwdhjSrdpd$17.3 Bil
HOLX
Hologic IncWdbhqdjcJnqcdl$17.2 Bil

Sponsor Center